Business Context and Reporting Period
This Form 8-K Current Report was filed by Emerald Bioscience, Inc. (formerly Nemus Bioscience, Inc.) on May 24, 2019. The filing discloses the entry into material definitive agreements regarding intellectual property licensing. Note: The request metadata references "Skye Bioscience, Inc.," but the filing text explicitly identifies the registrant as Emerald Bioscience, Inc.
Key Financial Metrics and Agreements
The filing details two Restated and Amended License Agreements with the University of Mississippi, School of Pharmacy (UM) for intellectual property related to UM 5050 and UM 8930. The agreements include the following financial terms:
- Upfront Payments: $100,000 for UM 5050 and $200,000 for UM 8930.
- Patent Allowance Fee: $200,000 due within 30 days of the first USPTO Notice of Allowance for UM 8930.
- Annual Maintenance Fee: $75,000 per agreement, payable on the anniversary of the effective date.
- Royalties: Mid-single digit percentage on net sales, plus a portion of sublicensing fees.
- Patent Costs: Company required to reimburse UM for incurred patent costs.
Material Changes and Milestone Payments
The agreements establish specific milestone payments contingent on regulatory progress:
- IND Submission: $100,000 within 30 days of the first Investigational New Drug Application (or equivalent) submission.
- NDA Submission (New Route): $200,000 within 30 days of the first New Drug Application (or equivalent) for a product with a different route of administration.
- NDA Approval (New Route): $400,000 within 30 days of approval for a product with a different route of administration.
The filing does not provide comparative financial data (revenue, profit, cash flow) as this is a current report on a specific event, not a periodic financial statement.
Outlook, Risks, and Contingencies
Termination Risks: UM may terminate the agreements for material breach, including failure to make payments, bankruptcy, dissolution, or failure to commercialize at least one product. The Company may terminate with 60 days' written notice.
Duration: Agreements continue until the later of the expiration of the last patent or the expiration of payment obligations.
Disclosure: A press release announcing these agreements was issued on May 29, 2019, under Regulation FD.
Investor Verification Checklist
- Verify the total immediate cash outflow required for upfront payments ($300,000 total).
- Confirm the Company's current cash position to ensure ability to meet the $75,000 annual maintenance fees per agreement.
- Review the specific definitions of "mid-single digits" for royalty rates in the full text of Exhibits 10.1 and 10.2.
- Assess the timeline for the first USPTO Notice of Allowance for UM 8930 to anticipate the $200,000 fee due within 30 days.
- Monitor the Company's progress on IND and NDA submissions to track potential future milestone liabilities.